BioRegenx, Inc. (BRGX)

Market Cap	8.99M -59.2%
Revenue (ttm)	1.77M -23.4%
Net Income	-1.30M
EPS	-0.00
Shares Out	971.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0093
Previous Close	0.0093
Day's Range	0.0093 - 0.0093
52-Week Range	0.0075 - 0.0300
Beta	-2.87
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About BioRegenx

BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a ...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: William Resides
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: BRGX

Financial Performance

In 2025, BioRegenx's revenue was $1.85 million, a decrease of -20.75% compared to the previous year's $2.34 million. Losses were -$1.54 million, -93.30% less than in 2024.